IBAB Ion Beam Applications SA

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION

 

 

(Article 14, paragr

aph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, January 31, 2024 01:00

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 25, 2024.

In its notification, NORGES BANK indicated that following an acquisition or disposal of securities or voting rights, downward crossing of the lowest threshold. Its total participation in IBA SA decreased and its participation in IBA shares with voting rights crossed the threshold of 1% on 23/01/2024.

Content of the notification

  • Reason for the notification: Acquisition or disposal of securities or voting rights

Downward crossing of the lowest threshold

  • Notification by: A person notifying alone
  • Persons subject to the notification requirement:
  • Date on which the threshold is crossed: 23/01/2024
  • Threshold crossed (in %) : 1%
  • Denominator : 40.595.290
  • Notified details: (extract of the received notification form)
  • Additional information

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reservesand is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for managementof the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting asprincipal and all holdings are registered in the name of Norges Bank.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

Valérie Van Impe

Paralegal



 

Attachment



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...

Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world’s most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...

 PRESS RELEASE

La protonthérapie, nouvelle norme de soins pour les patients atteints ...

La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch